Inogen Inc (INGN)

Currency in USD
6.60
-0.19(-2.80%)
Closed·
After Hours
6.600.00(0.00%)
·
INGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 8 days
Fair Value
Day's Range
6.506.81
52 wk Range
5.7013.33
Key Statistics
Prev. Close
6.6
Open
6.81
Day's Range
6.5-6.81
52 wk Range
5.7-13.33
Volume
193.42K
Average Volume (3m)
226.82K
1-Year Change
-29.49%
Book Value / Share
7.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.67
Upside
+76.77%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Inogen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Inogen Inc Company Profile

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Inogen Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue up 5.5% to $82.3M, beating $79M forecast; EPS of -$0.11 surpassed -$0.47 estimate
  • Gross margin improved to 44.2%; adjusted EBITDA turned positive at $36,000 from -$7.6M last year
  • Full-year 2025 revenue guidance set at $352M-$355M; Q2 projected at $89M-$91M
  • Stock rose 3.91% in aftermarket trading to $7.45; company maintains strong cash position with no debt
  • CEO highlights strategic priorities; CFO emphasizes realistic and achievable financial goals
Last Updated: 07/05/2025, 23:04
Read Full Transcript

Compare INGN to Peers and Sector

Metrics to compare
INGN
Peers
Sector
Relationship
P/E Ratio
−6.5x−3.1x−0.5x
PEG Ratio
−0.090.000.00
Price/Book
0.9x2.6x2.6x
Price / LTM Sales
0.5x4.1x3.2x
Upside (Analyst Target)
82.4%39.2%42.0%
Fair Value Upside
Unlock11.6%6.6%Unlock

Analyst Ratings

2 Buy
0 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.67
(+76.77% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.11 / -0.47
Revenue / Forecast
82.30M / 79.00M
EPS Revisions
Last 90 days

INGN Income Statement

People Also Watch

14.040
HMY
+1.23%
91.07
CIEN
+0.57%
43.69
OFG
-0.02%
14.68
CSTM
+5.38%
8.4500
OWLT
-0.24%

FAQ

What Stock Exchange Does Inogen Inc Trade On?

Inogen Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Inogen Inc?

The stock symbol for Inogen Inc is "INGN."

What Is the Inogen Inc Market Cap?

As of today, Inogen Inc market cap is 177.46M.

What Is Inogen Inc's Earnings Per Share (TTM)?

The Inogen Inc EPS (TTM) is -1.14.

When Is the Next Inogen Inc Earnings Date?

Inogen Inc will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is INGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Inogen Inc Stock Split?

Inogen Inc has split 0 times.

How Many Employees Does Inogen Inc Have?

Inogen Inc has 766 employees.

What is the current trading status of Inogen Inc (INGN)?

As of 30 Jul 2025, Inogen Inc (INGN) is trading at a price of 6.60, with a previous close of 6.60. The stock has fluctuated within a day range of 6.50 to 6.81, while its 52-week range spans from 5.70 to 13.33.

What Is Inogen Inc (INGN) Price Target According to Analysts?

The average 12-month price target for Inogen Inc is USD11.66667, with a high estimate of USD14 and a low estimate of USD9. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +76.77% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.